Key insights
- Agilent Technologies announced the transition of its Chief Legal Officer, Bret DiMarco, with a transition agreement extending through December 2026. While the company maintains financial stability with consistent dividend payments, leadership uncertainty could introduce short-term volatility. However, InvestingPro analysis suggests the stock is undervalued, potentially offsetting negative sentiment.
Agilent Technologies, Inc. (NYSE:A) reported a leadership transition involving its Chief Legal Officer on Monday, according to a statement based on a recent SEC filing. The $32.6 billion life sciences company, currently trading at $115.48, continues to demonstrate financial stability with a P/E ratio of 25.34 and a dividend yield of 0.88%.
The company announced that Bret DiMarco, Senior Vice President, Chief Legal Officer and Secretary, entered into a transition and general release agreement with Agilent on March 31, 2026. Under the terms of the agreement, Mr. DiMarco will resign from his current roles upon the earlier of the start date of a new Chief Legal Officer or September 30, 2026. He will continue with the company as a Special Advisor to provide transitional assistance through December 1, 2026.
While serving as Special Advisor, Mr. DiMarco will receive a base salary at an annualized rate of $350,000. He will remain eligible to participate in Agilent’s group health and welfare plans and will continue to vest in outstanding equity awards in accordance with their terms. Mr. DiMarco will not be eligible for additional equity grants or for the payment of an annual bonus for the company’s 2026 fiscal year.
Following the completion of his service as Special Advisor, and subject to execution and effectiveness of a supplemental release of claims, Mr. DiMarco will receive a lump sum payment equal to one times his current base salary and target bonus, less the amount of base salary paid during his service as Special Advisor.According to InvestingPro analysis, Agilent appears undervalued at current levels, with the company maintaining dividend payments for 15 consecutive years. Investors seeking deeper insights can access comprehensive Pro Research Reports covering Agilent and 1,400+ other US equities.
Agilent Technologies filed the transition and general release agreement as an exhibit to its current report on Form 8-K with the Securities and Exchange Commission.
In other recent news, Crawford & Company has announced several key developments. The company appointed W. Bruce Swain as its permanent president and CEO, a position he had been holding on an interim basis since January 2026. Additionally, Crawford named Jemin Thakkar as the global chief information officer, who will lead the company’s global IT and technology organization. In another strategic move, Crawford’s Contractor Connection partnered with Helixco to enhance its commercial repair program with real-time documentation technology.
Meanwhile, Agilent Technologies made significant strides with the launch of the BioTek Cytation 9 cell imaging multimode reader. This new instrument combines microplate reading and high-content cell imaging capabilities, offering twice the imaging speed of previous models. Agilent also announced the creation of Agilent Advanced Therapeutics, a unified contract development and manufacturing organization. This new business unit merges operations in Canada and the United States, enhancing their service offerings for pharmaceutical companies. These developments reflect the companies’ ongoing efforts to strengthen their leadership and expand technological capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.